HomeNewsBusinessAjinkya Rahane on why he became a startup investor and his rules for investing in companies

Ajinkya Rahane on why he became a startup investor and his rules for investing in companies

Cricketer Ajinkya Rahane shares for the first time details of his investment strategy and the vital factors that drive him to invest in a business

February 04, 2021 / 11:23 IST
Story continues below Advertisement

While cricket is his first love, Ajinkya Rahane, Vice-Captain of the Indian cricket team, did not shy away when he got the chance to don the investor hat. Rahane, who led underdog India to a stunning victory over Australia in the recent Test series Down Under, had last year invested in two startups, including the Mahindra-backed MeraKisan, an agri-tech startup, and Hudle, a digital platform for sports enthusiasts.

While MeraKisan supplies produce from farmers to consumers through retail stores as well as e-commerce platforms, Hudle helps sports enthusiasts find and book sporting events and venues.

Story continues below Advertisement

Ask Rahane why he decided to become an investor, and he says, “As cricketers, we get into a focused lifestyle at a very young age and most of our efforts are about consistently playing cricket whenever possible. As I played more cricket, I also got a chance to travel, meet new people, and hear about interesting businesses that people have developed.”

But there’s more to it.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show